GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cardiol Therapeutics
Cardiol Therapeutics is a biotech company developing cannabidiol (CBD)-based drugs for the treatment of heart disease. Its stock price reflects both the potential of its research and the regulatory challenges associated with cannabinoids.
Share prices of companies in the market segment - Heart
Cardiol Therapeutics is a biopharmaceutical company focused on developing anti-inflammatory and antifibrotic drugs for the treatment of heart disease. We classify it in the "Heart" sector. The chart below shows the dynamics of this important area of medicine.
Broad Market Index - GURU.Markets
Cardiol Therapeutics is a Canadian biotech company developing cannabidiol-based drugs for the treatment of cardiovascular diseases. As a unique player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Cardiol's performance.
Change in the price of a company, segment, and market as a whole per day
CRDL - Daily change in the company's share price Cardiol Therapeutics
Cardiol Therapeutics' daily share price fluctuations reflect the high volatility inherent in biotech companies operating in the cardiology sector. This metric measures sensitivity to clinical trial news, serving as a risk assessment tool.
Daily change in the price of a set of shares in a market segment - Heart
Cardiol Therapeutics' daily share price fluctuations reflect the high volatility inherent in biotech companies operating in the cardiology sector. This metric measures sensitivity to clinical trial news, serving as a risk assessment tool.
Daily change in the price of a broad market stock, index - GURU.Markets
Cardiol Therapeutics specializes in the treatment of cardiovascular diseases. Given the prevalence of these conditions, the company's developments attract considerable attention. Its shares are volatile and dependent on research progress, contributing to market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cardiol Therapeutics
Cardiol Therapeutics' year-end performance is a story about the development of cannabidiol (CBD)-based drugs for the treatment of heart disease. Its market capitalization over the next 12 months depends entirely on the results of clinical trials. Success could prove the therapeutic potential of CBD in cardiology and open up a huge market for the company.
Annual dynamics of market capitalization of the market segment - Heart
Cardiol Therapeutics Inc. is a Canadian biotechnology company focused on developing drugs for the treatment of cardiovascular diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cardiol is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its heart disease drug trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cardiol Therapeutics
Cardiol Therapeutics is developing cannabidiol-based drugs for the treatment of heart disease. Its monthly growth depends on the progress of its clinical trials. Trial results demonstrating the effectiveness of its drugs in myocarditis or heart failure are key.
Monthly dynamics of market capitalization of the market segment - Heart
Cardiol Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for cardiovascular diseases. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess how its research into the anti-inflammatory properties of cannabidiol (CBD) and the development of new cardiac drugs are progressing in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cardiol Therapeutics develops drugs to treat heart disease. Like many biotech companies, its shares react to internal events. The chart below illustrates how the company's monthly price fluctuations are driven not by general market sentiment, but by news about clinical trials and regulatory decisions.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cardiol Therapeutics
Cardiol Therapeutics, a biopharmaceutical company focused on treating heart disease, exhibits high volatility. Weekly stock performance depends on news about clinical trials of its drugs, where any event can dramatically change the company's outlook.
Weekly dynamics of market capitalization of the market segment - Heart
Cardiol Therapeutics focuses on treating heart disease with cannabidiol-based medications. This unique approach straddles two sectors. This chart helps you understand what influences the company more: general trends in cardiology or specific developments in the world of medical cannabis.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cardiol Therapeutics uses cannabidiol to treat heart disease. This sector is highly volatile and vulnerable to regulatory changes. The chart shows how CRDL shares move at their own pace, often defying broader market trends.
Market capitalization of the company, segment and market as a whole
CRDL - Market capitalization of the company Cardiol Therapeutics
The Cardiol Therapeutics chart is a financial map of the therapeutic potential of cannabidiol (CBD). The market cap of this company, which develops CBD-based drugs for the treatment of cardiovascular diseases, reflects its belief in the compound's medicinal properties. Its performance is a barometer of progress in clinical trials and the regulatory environment for cannabinoids.
CRDL - Share of the company's market capitalization Cardiol Therapeutics within the market segment - Heart
Cardiol Therapeutics' market share in the cardiology sector reflects its focus on treating heart diseases, particularly inflammatory conditions such as myocarditis. Its market share is based on the potential of its drug candidates, which may offer new therapeutic options in this area.
Market capitalization of the market segment - Heart
Cardiol Therapeutics is a biotech company focused on treating cardiovascular diseases. The chart below shows the overall market capitalization of the entire pharmaceutical industry. Its dynamics provide the backdrop against which Cardiol is seeking new approaches to treating heart disease.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cardiol Therapeutics is developing cannabidiol (CBD)-based drugs for the treatment of inflammatory heart diseases. Its market cap reflects the compound's medicinal potential. The chart below shows the economic weight of companies researching the therapeutic properties of cannabinoids.
Book value capitalization of the company, segment and market as a whole
CRDL - Book value capitalization of the company Cardiol Therapeutics
For Cardiol Therapeutics, which develops cannabidiol-based drugs, book value is its capital. The chart below isn't a story about factories, but about the financial resources for clinical trials. Its dynamics are the pulse of its scientific project in cardiology.
CRDL - Share of the company's book capitalization Cardiol Therapeutics within the market segment - Heart
Cardiol Therapeutics is a biotech company developing cannabidiol-based drugs for the treatment of heart disease. Its core capital is intellectual property. The share of physical assets chart will reflect its research-focused model, where patents are its primary assets.
Market segment balance sheet capitalization - Heart
Cardiol Therapeutics is a biopharmaceutical company focused on heart disease. Its value lies in clinical research, not manufacturing. This is a "light" model. The chart below shows the combined material "weight" of the entire biopharmaceutical industry, which highlights the company's focus on science.
Book value of all companies included in the broad market index - GURU.Markets
Cardiol Therapeutics' balance sheet represents capital focused on the research and development of cannabidiol-based drugs for the treatment of heart disease. The book value chart shows the resources devoted to exploring the therapeutic potential of this substance in cardiology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cardiol Therapeutics
Cardiol Therapeutics is developing cannabidiol (CBD)-based drugs for the treatment of heart disease. The company has no significant tangible assets. Its market capitalization is a bet on its ability to prove the therapeutic value of CBD in cardiology through clinical trials. The chart reflects the risks and potential of this unusual approach.
Market to book capitalization ratio in a market segment - Heart
Cardiol Therapeutics develops cannabidiol-based drugs for the treatment of cardiovascular diseases. It is a niche biopharmaceutical company. The chart shows how the market values its scientific approach and the potential of its drugs, which determines its value beyond its tangible assets.
Market to book capitalization ratio for the market as a whole
Cardiol Therapeutics is a biopharmaceutical company focused on developing treatments for heart disease. The chart shows how the market values the company, which targets one of the leading causes of death globally. Its market capitalization is based not on its assets, but on the potential of its drugs for the treatment of inflammatory heart diseases.
Debts of the company, segment and market as a whole
CRDL - Company debts Cardiol Therapeutics
Cardiol Therapeutics is a biopharmaceutical company focused on developing treatments for heart disease. Debt instruments are used by the company during clinical development to finance the lengthy and expensive trials required to obtain regulatory approval.
Market segment debts - Heart
Cardiol Therapeutics is a biopharmaceutical company focused on developing treatments for cardiovascular disease. It is one of the most common causes of death, creating a huge market. The chart shows the general financial metrics for the pharmaceutical sector, which are used as a backdrop for Cardiol to raise capital for clinical trials of its cardiac drugs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cardiol Therapeutics
Cardiol Therapeutics is developing cannabidiol-based drugs for the treatment of cardiovascular diseases. This is an innovative but still under-explored area. This chart shows the extent to which the company uses debt to finance its clinical research. This is an important indicator for assessing financial stability in the risky biotech sector.
Market segment debt to market segment book capitalization - Heart
Cardiol Therapeutics' development of cardiovascular drugs targets one of the leading causes of death worldwide. This chart shows the debt burden in the pharmaceutical industry. It allows one to assess how the financial strategy of a company focused on inflammatory heart diseases compares with that of cardiology market giants.
Debt to book value of all companies in the market
Cardiol Therapeutics focuses on treating heart disease. Developing drugs for such a critical area requires lengthy and expensive clinical trials. This chart allows us to assess how their debt burden, taken on to finance these trials, aligns with market norms for biopharma.
P/E of the company, segment and market as a whole
P/E - Cardiol Therapeutics
This figure for Cardiol Therapeutics, a biopharmaceutical company focused on treating heart disease, reflects investor expectations. For a company in the clinical development stage, its value is determined by the potential of its drugs. The chart is a barometer of confidence in its ability to offer new treatments.
P/E of the market segment - Heart
This indicator represents the average valuation for the biotech sector in which Cardiol Therapeutics operates. It reflects the overall level of hope and expectation in the field of cardiac treatment. The chart serves as a barometer of investor confidence in the future of cardiac drugs.
P/E of the market as a whole
Cardiol Therapeutics is a biopharmaceutical company developing cannabidiol (CBD)-based drugs for the treatment of cardiovascular diseases. This is an unusual use for a well-known substance. This chart shows the sentiment in the biotech industry. It helps understand whether the market believes in the scientific basis for this approach and how it assesses the risks associated with both clinical trials and cannabinoid regulation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cardiol Therapeutics
Cardiol Therapeutics is a biotech company focused on developing treatments for cardiovascular disease. Its lead product is based on cannabidiol (CBD) for the treatment of inflammatory heart diseases. The company's future depends on the results of clinical trials. This chart shows how investors view the potential of its unique approach to cardiology.
%20P%2FE%20Cardiol%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cardiol-Therapeutics&v=1772637696342 "Chart of the company's future (projected) P/E Cardiol Therapeutics")
Future (projected) P/E of the market segment - Heart
Cardiol Therapeutics is a biopharmaceutical company focused on developing treatments for cardiovascular disease. Its lead candidate is based on cannabidiol (CBD) due to its anti-inflammatory properties. The chart reflects expectations for the biotech sector, helping to assess how the market views this innovative approach to treating heart disease.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Heart&v=1772637696347 "Future (projected) P/E graph of the market segment - Heart")
Future (projected) P/E of the market as a whole
Cardiol Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of cardiovascular diseases. Their lead candidate targets inflammatory processes in the heart. This graph of overall expectations shows how willing investors are to invest in medicine. Market optimism facilitates raising capital for clinical trials targeting one of the leading causes of death worldwide.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772637696357 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cardiol Therapeutics
Cardiol Therapeutics is a biopharmaceutical company developing cannabidiol (CBD)-based drugs for the treatment of cardiovascular diseases. This chart reflects the financial health of the company, which is researching the therapeutic potential of cannabinoids. Profitability depends on the results of clinical trials demonstrating the efficacy and safety of its approaches.
Profit of companies in the market segment - Heart
Generation Bio Co. is developing a gene therapy platform that doesn't require viruses to deliver genetic material. This is a potentially safer approach. This graph reflects the state of the art in gene therapy, where scientific breakthroughs can solve key problems with existing technologies, but the path to profitability requires years of research and billions of dollars.
Overall market profit
Cardiol Therapeutics is a biotech company focused on developing drugs to treat cardiovascular diseases such as myocarditis. Given the prevalence of heart disease, the potential market for its products is enormous. However, as with any biotech company, success depends on clinical trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cardiol Therapeutics
Cardiol Therapeutics is a biotech company focused on developing cannabidiol (CBD)-based drugs for the treatment of heart disease. Its profit forecast depends on the results of clinical trials demonstrating the effectiveness of its approaches. This chart reflects analyst expectations regarding the potential of CBD in cardiology and the company's progress.
%20profit%20of%20the%20company%20Cardiol%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cardiol-Therapeutics&v=1772637696502 "Graph of future (projected) profit of the company Cardiol Therapeutics")
Future (predicted) profit of companies in the market segment - Heart
Cardiol Therapeutics is a biopharmaceutical company developing cannabidiol (CBD)-based drugs for the treatment of cardiovascular diseases such as pericarditis and myocarditis. This chart shows profitability forecasts for the pharmaceutical sector. It reflects the market's belief in the therapeutic potential of cannabinoids beyond their traditional uses.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Heart&v=1772637696523 "Graph of future (predicted) profits of companies in a market segment - Heart")
Future (predicted) profit of the market as a whole
Cardiol Therapeutics is focused on treating cardiovascular diseases using cannabidiol. Demand for its potential drugs will be determined by medical indications. However, the overall profit expectations shown in this chart impact the availability of capital for costly clinical trials in the pharmaceutical industry.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772637696534 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cardiol Therapeutics
Cardiol Therapeutics is a biopharmaceutical company focused on developing cannabidiol (CBD)-based drugs for the treatment of cardiovascular diseases, particularly inflammatory conditions in the heart. The chart shows how investors assess the scientific prospects and potential therapeutic market for its developments, which are not yet revenue-generating.
P/S market segment - Heart
Cardiol Therapeutics is a clinical-stage biopharmaceutical company developing treatments for cardiovascular diseases. Its lead candidate is based on cannabidiol for the treatment of inflammatory heart diseases. This chart shows the average valuation in the sector, allowing one to assess how the market perceives Cardiol's potential.
P/S of the market as a whole
Cardiol Therapeutics is a biopharmaceutical company focused on developing treatments for cardiovascular diseases. Its lead candidate targets inflammatory processes in the heart. This chart, reflecting the average estimated real revenue, clearly highlights how biotech investments are betting on scientific breakthroughs in cardiology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cardiol Therapeutics
Cardiol Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of cardiovascular diseases. This chart reflects investor expectations for the future commercial potential of its lead candidate, a cannabidiol-based drug. The assessment is based on its anticipated use in the treatment of inflammatory heart diseases.
%20P%2FS%20Cardiol%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cardiol-Therapeutics&v=1772637696577 "The graph of the company's future (projected) P/S Cardiol Therapeutics")
Future (projected) P/S of the market segment - Heart
Cardiol Therapeutics is a biopharmaceutical company focused on developing cannabidiol (CBD)-based drugs for the treatment of cardiovascular diseases such as myocarditis. This chart shows how the market estimates Cardiol's future sales, reflecting confidence in the therapeutic potential of CBD and the success of its clinical programs.
%20P%2FS%20market%20segment%20graph%20-%20Heart&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Heart&v=1772637696584 "Future (projected) P/S market segment graph - Heart")
Future (projected) P/S of the market as a whole
This chart reflects investor confidence in the potential of cannabinoids to treat serious diseases. Cardiol Therapeutics is focused on developing cannabidiol (CBD)-based drugs for the treatment of cardiovascular diseases such as myocarditis. Their scientific approach to studying the properties of cannabinoids supports optimism regarding the therapeutic potential of this class of compounds.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772637696603 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cardiol Therapeutics
Cardiol Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cardiovascular diseases. At this stage, its revenue is minimal or nonexistent, as its key drugs are in clinical trials. This chart reflects the research and development phase, not commercial sales.
Sales of companies in the market segment - Heart
Cardiol Therapeutics is a biopharmaceutical company focused on developing cannabidiol (CBD)-based anti-inflammatory drugs for the treatment of cardiovascular disease. This chart shows total revenue in the cardiology segment. It reflects the vast market and the need for new heart disease treatments, where Cardiol is exploring a unique approach.
Overall market sales
Cardiol Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of cardiovascular diseases. Its lead candidate is based on cannabidiol. The company's success depends on the results of clinical trials. This overall economic situation influences overall healthcare spending and investment interest in new heart disease treatments.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cardiol Therapeutics
Cardiol Therapeutics is a biopharmaceutical company focused on developing cannabidiol (CBD)-based drugs for the treatment of cardiovascular diseases such as myocarditis. Success depends on clinical data. The chart shows speculative revenue projections, betting on the therapeutic potential of CBD for heart disease.
%20sales%20of%20the%20company%20Cardiol%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cardiol-Therapeutics&v=1772637696658 "Schedule of future (projected) sales of the company Cardiol Therapeutics")
Future (projected) sales of companies in the market segment - Heart
Cardiol Therapeutics is a biopharmaceutical company focused on developing cannabidiol (CBD)-based drugs for the treatment of cardiovascular diseases such as myocarditis. Success depends on clinical trials. This chart displays projected sales for the entire cardiac drug segment, highlighting overall growth expectations for this important market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Heart&v=1772637696662 "Schedule of future (projected) sales of companies in the market segment - Heart")
Future (projected) sales of the market as a whole
Cardiol Therapeutics is a biopharmaceutical company focused on developing cannabidiol (CBD)-based drugs for the treatment of cardiovascular diseases. The company's success depends on the results of clinical trials. This overall economic activity profile influences investor willingness to fund research in new, unexplored areas of medicine.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772637696681 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cardiol Therapeutics
Cardiol Therapeutics is a biotechnology company focused on developing drugs for the treatment of cardiovascular diseases. This metric is a financial reflection of its research activity, demonstrating the amount of investment in clinical trials required to bring new heart disease treatments to market.
Market segment marginality - Heart
Cardiol Therapeutics is a biopharmaceutical company focused on developing cannabidiol-based drugs for the treatment of cardiovascular diseases. Profitability will depend on the success of clinical trials. This metric reflects the company's operational structure in this innovative field of cardiology.
Market marginality as a whole
Cardiol Therapeutics is a biopharmaceutical company focused on developing treatments for cardiovascular diseases. Their lead candidate is based on pharmaceutical-grade cannabidiol (CBD). Their success depends on the results of clinical trials. This overall profitability curve doesn't affect their research activities, but it is important for attracting investment.
Employees in the company, segment and market as a whole
Number of employees in the company Cardiol Therapeutics
Cardiol Therapeutics is developing cannabidiol (CBD)-based drugs for the treatment of cardiovascular diseases. The company is in the clinical stage and has a small staff. This chart shows the dynamics of the team of scientists and clinical trial managers leading research in this unconventional but promising area of medicine.
Share of the company's employees Cardiol Therapeutics within the market segment - Heart
Cardiol Therapeutics is focused on developing cannabidiol (CBD)-based treatments for cardiovascular disease. This chart shows the percentage of clinicians and scientists researching the therapeutic potential of cannabinoids in cardiology that the company is attracting. Its team is exploring a new frontier in heart disease treatment.
Number of employees in the market segment - Heart
Cardiol Therapeutics is a biopharmaceutical company focused on developing anti-inflammatory drugs for the treatment of cardiovascular diseases. This chart shows overall employment in the cardiology sector. It illustrates the search for new approaches to treating heart disease, where Cardiol is focusing on reducing inflammation as a key therapeutic factor.
Number of employees in the market as a whole
Cardiol Therapeutics is a pharmaceutical company focused on the research and development of anti-inflammatory drugs for the treatment of heart disease. Cardiovascular disease is a leading cause of death. This graph illustrates the labor market, where the healthcare sector plays a significant role, and such companies create a demand for cardiologists, scientists, and clinical research specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cardiol Therapeutics (CRDL)
Cardiol Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of heart disease. This chart demonstrates the market's high valuation of its scientific potential. In biotech, high market capitalization per employee is the norm, as a company's value comes from its R&D portfolio and patents, not its operating activities.
%20of%20the%20company%20Cardiol%20Therapeutics%20(CRDL)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cardiol-Therapeutics-CRDL&v=1772637696825 "Chart of market capitalization per employee (in thousands of dollars) of the company Cardiol Therapeutics (CRDL)")
Market capitalization per employee (in thousands of dollars) in the market segment - Heart
Cardiol Therapeutics is a pharmaceutical company focused on treating cardiovascular diseases. Their value depends on the success of their drugs' clinical trials. This metric reflects how investors assess the company's scientific potential relative to its team. A high metric indicates high hopes that their developments will become a new standard in cardiology.
%20by%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Heart&v=1772637696859 "Market capitalization per employee (in thousands of dollars) by market segment - Heart")
Market capitalization per employee (in thousands of dollars) for the overall market
Cardiol Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of cardiovascular diseases. Its valuation is dependent on the results of clinical trials. This metric reflects the typical biotech dynamics, where market capitalization outpaces actual revenue in anticipation of the approval of a new, important drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772637696880 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cardiol Therapeutics (CRDL)
Cardiol Therapeutics is a biotech company developing drugs to treat cardiovascular diseases such as myocarditis. It's an R&D company targeting a large market. This metric reflects their current phase, showing their net loss (clinical trial costs) per employee.
%20Chart%20Cardiol%20Therapeutics%20(CRDL)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cardiol-Therapeutics-CRDL&v=1772637696910 "Company Profit Per Employee (in thousands of dollars) Chart Cardiol Therapeutics (CRDL)")
Profit per employee (in thousands of dollars) in the market segment - Heart
Cardiol Therapeutics is a biotech company focused on treating cardiovascular diseases. During the R&D phase, this profit per employee metric is negative. This graph serves as a benchmark for the future. Success will depend on the results of clinical trials. If approved, their drugs could generate profits that exceed the industry benchmark by several times.
%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Heart&v=1772637696913 "Chart of profit per employee (in thousands of dollars) in the market segment - Heart")
Profit per employee (in thousands of dollars) for the market as a whole
Cardiol Therapeutics (CRDL) is a biopharmaceutical company focused on treating cardiovascular diseases. They are researching drugs that target inflammation in the heart. This chart illustrates their current status: the company is in the clinical stage, and its entire team generates R&D expenses, not profits.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772637696924 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cardiol Therapeutics (CRDL)
For Cardiol Therapeutics, a company developing cannabidiol-based drugs for the treatment of heart disease, this graph reflects research progress. Potential revenue growth per employee is driven by the successful demonstration of efficacy of its candidates in clinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cardiol-Therapeutics-CRDL&v=1772637696929 "Sales chart per company employee Cardiol Therapeutics (CRDL)")
Sales per employee in the market segment - Heart
Cardiol Therapeutics is a biopharmaceutical company focused on developing cardiovascular treatments, particularly those based on cannabidiol. This metric reflects the average revenue per employee for the segment. It allows us to assess how productive Cardiol's R&D team is in its niche compared to other cardiac biotechs.
Sales per employee for the market as a whole
Cardiol Therapeutics (CRDL) is a biopharmaceutical company focused on developing treatments for cardiovascular diseases. Currently, its staff consists primarily of scientists and researchers. This metric is particularly interesting for CRDL: it reflects the transition from pure R&D to commercialization. Until a drug is approved, this value is close to zero.
Short shares by company, segment and market as a whole
Shares shorted by company Cardiol Therapeutics (CRDL)
Cardiol Therapeutics is a biotech company researching the use of cannabidiol (CBD) to treat cardiovascular disease. This hypothesis still requires robust clinical evidence. This chart shows how many investors are skeptical of CBD's therapeutic potential in cardiology and are betting on the failure of its clinical programs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cardiol-Therapeutics-CRDL&v=1772637697062 "Short Shares Chart for the Company Cardiol Therapeutics (CRDL)")
Shares shorted by market segment - Heart
Cardiol Therapeutics (CRDL) is a biopharmaceutical company developing treatments for heart disease, particularly inflammatory conditions such as myocarditis, using cannabidiol (CBD). This chart shows the overall short position in the cardiac drug sector. It reflects market skepticism about the therapeutic potential of CBD for such serious conditions.
Shares shorted by the overall market
Cardiol Therapeutics (CRDL) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cardiol Therapeutics (CRDL)
Cardiol Therapeutics (CRDL) is a biotech company making a unique bet: treating heart disease with cannabidiol (CBD). It's a speculative R&D bet at the intersection of pharmaceuticals and cannabis. This chart measures the level of hype. It shows when data euphoria (overbought) or doubts (oversold) reach a peak.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cardiol-Therapeutics-CRDL&v=1772637697106 "RSI 14 indicator chart for the company's stock Cardiol Therapeutics (CRDL)")
RSI 14 Market Segment - Heart
Cardiol (CRDL) is a "biotech" company focused on the heart. They are developing cannabidiol (CBD) to treat inflammatory heart diseases (myocarditis). The Heart (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand whether CRDL's growth is just their "CBD niche" or whether the entire biotech sector is overheated.
RSI 14 for the overall market
Cardiol Therapeutics (CRDL) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CRDL (Cardiol Therapeutics)
Cardiol Therapeutics is a Canadian biopharmaceutical company focused on treating heart disease. Its key candidate is pure cannabidiol (CBD) for the treatment of inflammatory heart disease (pericarditis). This chart shows the speculative average price target from analysts based on their confidence in this R&D.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CRDL-Cardiol-Therapeutics&v=1772637697193 "A chart showing analyst consensus forecasts for the expected stock price. CRDL (Cardiol Therapeutics)")
The difference between the consensus estimate and the actual stock price CRDL (Cardiol Therapeutics)
Cardiol Therapeutics is a Canadian biopharmaceutical company researching the anti-inflammatory and anti-fibrotic properties of cannabidiol (CBD) for the treatment of heart disease. This chart shows how the current share price differs from the "fair" value predicted by analysts. It reflects their view on this unique R&D project.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CRDL-Cardiol-Therapeutics&v=1772637697199 "A chart showing the difference between the consensus forecast and the actual stock price. CRDL (Cardiol Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Heart
Cardiol Therapeutics (CRDL) is a Canadian biotech company developing cannabidiol (CBD)-based drugs for the treatment of inflammatory heart diseases (myocarditis, pericarditis). This chart shows general expectations for the cardiology sector. It reflects whether experts believe in the medical potential of CBD.
Analysts' consensus forecast for the overall market share price
Cardiol Therapeutics is a Canadian biotech company specializing in the development of cannabidiol (CBD)-based drugs for the treatment of cardiovascular disease (heart inflammation). This chart shows the overall risk appetite. For Cardiol, which operates at the intersection of biotech and cannabis, overall market optimism is important for funding clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cardiol Therapeutics
Cardiol (CRDL) is a Canadian biotech company. Their signature product is cannabidiol (CBD). They don't sell weed, but in clinical trials, they demonstrate that their pharmaceutical-grade (pure) CBD can treat heart conditions (pericarditis, myocarditis). This graph represents their R&D bet. It measures their ability to transform CBD from a folk remedy into a viable medicine.
AKIMA Market Segment Index - Heart
Cardiol Therapeutics is a Canadian company specializing in the development of cannabidiol (CBD)-based drugs for the treatment of cardiovascular diseases such as myocarditis. This chart shows the average index for the cardiac segment. It helps investors assess how Cardiol's niche approach compares to the industry average.
The AKIM Index for the overall market
Cardiol Therapeutics is a biopharmaceutical company researching the use of pure cannabidiol to treat inflammatory heart diseases (pericarditis). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical development in cardiology compares to overall economic trends and sector sentiment.
